Edward Gudaitis CEO of Acerus Pharmaceuticals: New CEO Has Big Plans for Company's Future

TL;DR

Saris Pharmaceuticals is a specialty pharmaceutical company that aims to expand its R&D pipeline, optimize commercial products, and grow in multiple therapeutic areas.

Transcript

this is Gabriela Cousteau with the investing news network I'm here in Toronto at the Blum Burton healthcare investor conference and right now I'm speaking with Edward good itis with us Eris pharmaceuticals thank you for being here today Edward thank you very much Gabrielle it's a pleasure to be interviewed today first we really want investors to ge... Read More

Key Insights

• 🌐 Saris Pharmaceuticals is a specialty pharmaceutical company with a global reach, covering all aspects of drug development and commercialization.
• 👶 The company's new CEO, Edward Gooditis, seeks to propel the company's growth by advancing the R&D pipeline, optimizing commercial products, and diversifying into multiple therapeutic areas.
• 🍉 Investor opportunities exist in the short and medium term, with the company poised for growth and a bright future.
• 😇 Upcoming milestones include a cannabinoid initiative and the utilization of a nasal gel delivery platform for various products.
• 😷 Partnerships, such as the one with medic in Europe, present further growth opportunities for Saris Pharmaceuticals.
• 😥 Steady growth is expected in the next couple of years, and by 2020, the company anticipates inflection point growth with an expanded product portfolio and territories.
• 🌐 Saris Pharmaceuticals has the potential to become a Canadian specialty company with global presence and reach.

Questions & Answers

Q: What is Saris Pharmaceuticals and what sets it apart from other pharmaceutical companies?

Saris Pharmaceuticals is a specialty pharmaceutical company that aims to bridge the gap between big pharma players and smaller organizations. It covers all aspects of drug development and commercialization, with a dedicated team and partnerships worldwide.

Q: What impact does Edward Gooditis hope to have as the new CEO of Saris Pharmaceuticals?

Edward Gooditis aims to significantly advance the R&D pipeline, optimize commercial products, and grow the company's presence in the US and worldwide. He also intends to diversify into multiple therapeutic areas to ensure future growth and success.

Q: What milestones can investors look forward to in Saris Pharmaceuticals' pipeline?

Saris Pharmaceuticals recently announced a cannabinoid initiative and plans to utilize a nasal gel delivery platform for its core product, 'no testo.' More news and details about these initiatives are expected in the coming year. Additionally, the company is exploring other products within the nasal gel technology.

Q: What kind of growth should investors expect from Saris Pharmaceuticals in the next couple of years?

Saris Pharmaceuticals anticipates steady growth in 2019, with its testosterone product gaining traction in Canada and natural health products contributing to the top line. By 2020, the company expects inflective growth, expanding its product portfolio and territories.

Summary & Key Takeaways

• Saris Pharmaceuticals is a specialty pharmaceutical company based in Mississauga, Ontario with 28 dedicated employees and $6 million in current revenue.

• The company covers all aspects of drug development and commercialization, with a commercial team selling in Canada, partners selling in the US and worldwide, and an active R&D program.

• Edward Gooditis, the new CEO, plans to take Saris Pharmaceuticals to the next level by significantly advancing the R&D pipeline, optimizing commercial products, and expanding into multiple therapeutic areas.